{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T12:23:32Z","timestamp":1792499012314,"version":"4.5.0"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T00:00:00Z","timestamp":1625011200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Pediatr Rheumatol"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>H syndrome (HS) is a rare autoinflammatory disease caused by a mutation in the solute carrier family 29, member 3 (SCL29A3) gene. It has a variable clinical presentation and little phenotype-genotype correlation. The pathognomonic sign of HS is cutaneous hyperpigmentation located mainly in the inner thighs and often accompanied by other systemic manifestations. Improvement after tocilizumab treatment has been reported in a few patients with HS. We report the first patient with HS who presented cardiogenic shock, multiorgan infiltration, and digital ischemia.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>8-year-old boy born to consanguineous parents of Moroccan origin who was admitted to the intensive care unit during the Coronavirus Disease-2019 (COVID-19) pandemic with tachypnoea, tachycardia, and oliguria.<\/jats:p>\n                    <jats:p>Echocardiography showed dilated cardiomyopathy and severe systolic dysfunction compatible with cardiogenic shock. Additionally, he presented with multiple organ dysfunction syndrome. SARS-CoV-2 polymerase chain reaction (PCR) and antibody detection by chromatographic immunoassay were negative.<\/jats:p>\n                    <jats:p>A previously ordered gene panel for pre-existing sensorineural hearing loss showed a pathological mutation in the SCL29A3 gene compatible with H syndrome.<\/jats:p>\n                    <jats:p>Computed tomography scan revealed extensive alveolar infiltrates in the lungs and multiple poor defined hypodense lesions in liver, spleen, and kidneys; adenopathy; and cardiomegaly with left ventricle subendocardial nodules.<\/jats:p>\n                    <jats:p>Invasive mechanical ventilation, broad antibiotic and antifungal coverage showed no significant response. Therefore, Tocilizumab as compassionate use together with pulsed intravenous methylprednisolone was initiated. Improvement was impressive leading to normalization of inflammation markers, liver and kidney function, and stabilising heart function. Two weeks later, he was discharged and has been clinically well since then on two weekly administration of Tocilizumab.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>We report the most severe disease course produced by HS described so far in the literature. Our patient\u2019s manifestations included uncommon, new complications such as acute heart failure with severe systolic dysfunction, multi-organ cell infiltrate, and digital ischemia.<\/jats:p>\n                    <jats:p>Most of the clinical symptoms of our patient could have been explained by SARS-CoV-2, demonstrating the importance of a detailed differential diagnosis to ensure optimal treatment.<\/jats:p>\n                    <jats:p>Although the mechanism of autoinflammation of HS remains uncertain, the good response of our patient to Tocilizumab makes a case for the important role of IL-6 in this syndrome and for considering Tocilizumab as a first-line treatment, at least in severely affected patients.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12969-021-00586-2","type":"journal-article","created":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T09:02:56Z","timestamp":1625043776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Patient with H syndrome, cardiogenic shock, multiorgan infiltration, and digital ischemia"],"prefix":"10.1186","volume":"19","author":[{"given":"Laura","family":"Ventura-Espejo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"In\u00e9s","family":"Gracia-Darder","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvia","family":"Escrib\u00e1-Bori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eva Regina","family":"Amador-Gonz\u00e1lez","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Mart\u00edn-Santiago","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3784-6846","authenticated-orcid":false,"given":"Jan","family":"Ramakers","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,6,30]]},"reference":[{"issue":"4","key":"586_CR1","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1016\/j.ajhg.2008.09.013","volume":"83","author":"V Molho-Pessach","year":"2008","unstructured":"Molho-Pessach V, Lerer I, Abeliovich D, Agha Z, Abu Libdeh A, Broshtilova V, et al. The H syndrome is caused by mutations in the nucleoside transporter hENT3. Am J Hum Genet. 2008;83(4):529\u201334. https:\/\/doi.org\/10.1016\/j.ajhg.2008.09.013.","journal-title":"Am J Hum Genet"},{"key":"586_CR2","doi-asserted-by":"publisher","unstructured":"Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, et al. The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol. 2008; [cited 2020 Apr 19];59(1):79\u201385. Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/18410979,\u00a0https:\/\/doi.org\/10.1016\/j.jaad.2008.03.021.","DOI":"10.1016\/j.jaad.2008.03.021"},{"issue":"1","key":"586_CR3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12969-017-0204-y","volume":"15","author":"JL Bloom","year":"2017","unstructured":"Bloom JL, Lin C, Imundo L, Guthery S, Stepenaskie S, Galambos C, et al. H syndrome: 5 new cases from the United States with novel features and responses to therapy. Pediatr Rheumatol. 2017;15(1):1\u201312.","journal-title":"Pediatr Rheumatol"},{"issue":"8","key":"586_CR4","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1111\/1346-8138.14359","volume":"45","author":"H Jaouadi","year":"2018","unstructured":"Jaouadi H, Zaouak A, Sellami K, Messaoud O, Chargui M, Hammami H, et al. H syndrome: clinical, histological and genetic investigation in Tunisian patients. J Dermatol. 2018;45(8):978\u201385. https:\/\/doi.org\/10.1111\/1346-8138.14359.","journal-title":"J Dermatol"},{"issue":"4","key":"586_CR5","doi-asserted-by":"publisher","first-page":"186","DOI":"10.1159\/000475908","volume":"151","author":"S Vural","year":"2017","unstructured":"Vural S, Ertop P, Durmaz CD, \u015eanll H, Ok\u00e7u Heper A, Kundak\u00e7l N, et al. Skin-dominant phenotype in a patient with H syndrome: identification of a novel mutation in the SLC29A3 gene. Cytogenet Genome Res. 2017;151(4):186\u201390. https:\/\/doi.org\/10.1159\/000475908.","journal-title":"Cytogenet Genome Res"},{"issue":"6","key":"586_CR6","doi-asserted-by":"publisher","first-page":"494","DOI":"10.1016\/j.rchipe.2016.03.006","volume":"87","author":"HH Abarca Barriga","year":"2016","unstructured":"Abarca Barriga HH, Trubnykova M, Polar C\u00f3rdoba V, Ramos Diaz KJ, Aviles AN. S\u00edndrome H: primer caso pedi\u00e1trico reportado en Am\u00e9rica Latina. Rev Chil Pediatr. 2016;87(6):494\u20139. Available from:. https:\/\/doi.org\/10.1016\/j.rchipe.2016.03.006.","journal-title":"Rev Chil Pediatr"},{"issue":"4","key":"586_CR7","doi-asserted-by":"publisher","first-page":"305","DOI":"10.1111\/pedi.12160","volume":"16","author":"M Al-Haggar","year":"2015","unstructured":"Al-Haggar M, Salem N, Wahba Y, Ahmad N, Jonard L, Abdel-Hady D, et al. Novel homozygous SLC29A3 mutations among two unrelated Egyptian families with spectral features of H-syndrome. Pediatr Diabetes. 2015;16(4):305\u201316. https:\/\/doi.org\/10.1111\/pedi.12160.","journal-title":"Pediatr Diabetes"},{"key":"586_CR8","doi-asserted-by":"publisher","unstructured":"Rafiq NK, Hussain K, Brogan PA. Tocilizumab for the Treatment of SLC29A3 Mutation Positive PHID Syndrome. Pediatrics. 2017;140(5):e20163148. https:\/\/doi.org\/10.1542\/peds.2016-3148.","DOI":"10.1542\/peds.2016-3148"},{"issue":"3","key":"586_CR9","doi-asserted-by":"publisher","first-page":"281","DOI":"10.1016\/j.diabet.2013.03.007","volume":"39","author":"J De Jesus","year":"2013","unstructured":"De Jesus J, Imane Z, Sen\u00e9e V, Romero S, Guillausseau PJ, Balafrej A, et al. SLC29A3 mutation in a patient with syndromic diabetes with features of pigmented hypertrichotic dermatosis with insulin-dependent diabetes, H syndrome and Faisalabad histiocytosis. Diabetes Metab. 2013;39(3):281\u20135. Available from:. https:\/\/doi.org\/10.1016\/j.diabet.2013.03.007.","journal-title":"Diabetes Metab"},{"key":"586_CR10","doi-asserted-by":"publisher","unstructured":"Melki I, Lambot K, Jonard L, Couloigner V, Quartier P, Neven B, Bader-Meunier B. Mutation in the SLC29A3 gene: a new cause of a monogenic, autoinflammatory condition. Pediatrics. 2013;131(4):e1308-13. https:\/\/doi.org\/10.1542\/peds.2012-2255. Epub 2013 Mar 25.","DOI":"10.1542\/peds.2012-2255"},{"issue":"10","key":"586_CR11","doi-asserted-by":"publisher","first-page":"1336","DOI":"10.4103\/0366-6999.156778","volume":"128","author":"JW Liu","year":"2015","unstructured":"Liu JW, Si N, Wang LQ, Shen T, Zeng XJ, Zhang X, et al. Identification of a novel mutation in solute carrier family 29, member 3 in a Chinese patient with H syndrome. Chin Med J. 2015;128(10):1336\u20139. https:\/\/doi.org\/10.4103\/0366-6999.156778.","journal-title":"Chin Med J"},{"issue":"8","key":"586_CR12","doi-asserted-by":"publisher","first-page":"1021","DOI":"10.2340\/00015555-2145","volume":"95","author":"B Tekin","year":"2015","unstructured":"Tekin B, Atay Z, Ergun T, Can M, Tuney D, Babay S, et al. H syndrome: a multifaceted histiocytic disorder with hyperpigmentation and hypertrichosis. Acta Derm Venereol. 2015;95(8):1021\u20133. https:\/\/doi.org\/10.2340\/00015555-2145.","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"586_CR13","doi-asserted-by":"publisher","first-page":"80","DOI":"10.1016\/j.jaad.2013.09.019","volume":"70","author":"V Molho-Pessach","year":"2014","unstructured":"Molho-Pessach V, Ramot Y, Camille F, Doviner V, Babay S, Luis SJ, et al. H syndrome: The first 79 patients. J Am Acad Dermatol. 2014;70(1):80\u20138. Available from:. https:\/\/doi.org\/10.1016\/j.jaad.2013.09.019.","journal-title":"J Am Acad Dermatol"},{"issue":"1","key":"586_CR14","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1007\/s12098-015-1776-5","volume":"83","author":"R Deshpande","year":"2016","unstructured":"Deshpande R, Parthasarathy L, Dalal A, Khadilkar V, Khadilkar A. Variability in the manifestations and evolution of symptoms in a patient with H syndrome. Indian J Pediatr. 2016;83(1):92\u20133. https:\/\/doi.org\/10.1007\/s12098-015-1776-5.","journal-title":"Indian J Pediatr"},{"key":"586_CR15","doi-asserted-by":"publisher","unstructured":"Shankarappa RK, Ananthakrishna R, Math RS, Yalagudri SD, Karur S, Dwarakaprasad R, Nanjappa MC, Molho-Pessach V. Accelerated coronary atherosclerosis and H syndrome. BMJ Case Rep. 2011;2011:bcr0320114019.\u00a0 https:\/\/doi.org\/10.1136\/bcr.03.2011.4019.","DOI":"10.1136\/bcr.03.2011.4019"},{"issue":"9\u201310","key":"586_CR16","doi-asserted-by":"publisher","first-page":"877","DOI":"10.1515\/jpem-2013-0062","volume":"26","author":"S Senniappan","year":"2013","unstructured":"Senniappan S, Hughes M, Shah P, Shah V, Kaski JP, Brogan P, et al. Pigmentary hypertrichosis and non-autoimmune insulin-dependent diabetes mellitus (PHID) syndrome is associated with severe chronic inflammation and cardiomyopathy, and represents a new monogenic autoinflammatory syndrome. J Pediatr Endocrinol Metab. 2013;26(9\u201310):877\u201382. https:\/\/doi.org\/10.1515\/jpem-2013-0062.","journal-title":"J Pediatr Endocrinol Metab"},{"issue":"1","key":"586_CR17","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.jaad.2008.03.021","volume":"59","author":"V Molho-Pessach","year":"2008","unstructured":"Molho-Pessach V, Agha Z, Aamar S, Glaser B, Doviner V, Hiller N, et al. The H syndrome: a genodermatosis characterized by indurated, hyperpigmented, and hypertrichotic skin with systemic manifestations. J Am Acad Dermatol. 2008;59(1):79\u201385. https:\/\/doi.org\/10.1016\/j.jaad.2008.03.021.","journal-title":"J Am Acad Dermatol"},{"key":"586_CR18","doi-asserted-by":"publisher","unstructured":"Galv\u00e1n Casas C, Catal\u00e0 A, Carretero Hern\u00e1ndez G, Rodr\u00edguez-Jim\u00e9nez P, Fern\u00e1ndez Nieto D, Rodr\u00edguez-Villa Lario A, et al. Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases. Br J Dermatol. 2020:0\u20133 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32348545,\u00a0https:\/\/doi.org\/10.1111\/bjd.19163.","DOI":"10.1111\/bjd.19163"},{"issue":"36","key":"586_CR19","doi-asserted-by":"publisher","first-page":"28343","DOI":"10.1074\/jbc.M110.109199","volume":"285","author":"N Kang","year":"2010","unstructured":"Kang N, Jun AH, Bhutia YD, Kannan N, Unadkat JD, Govindarajan R. Human equilibrative nucleoside transporter-3 (hENT3) spectrum disorder mutations impair nucleoside transport, protein localization, and stability. J Biol Chem. 2010;285(36):28343\u201352. https:\/\/doi.org\/10.1074\/jbc.M110.109199.","journal-title":"J Biol Chem"},{"key":"586_CR20","doi-asserted-by":"publisher","unstructured":"Hsu CL, Lin W, Seshasayee D, Chen YH, Ding X, Lin Z, et al. Equilibrative nucleoside transporter 3 deficiency perturbs lysosome function and macrophage homeostasis. Science (80-). 2012; [cited 2021 Feb 25];335(6064):89\u201392. Available from: https:\/\/science.sciencemag.org\/content\/335\/6064\/89,\u00a0https:\/\/doi.org\/10.1126\/science.1213682.","DOI":"10.1126\/science.1213682"},{"key":"586_CR21","doi-asserted-by":"publisher","unstructured":"Morgan NV, Morris MR, Cangul H, Gleeson D, Straatman-Iwanowska A, Davies N, Keenan S, Pasha S, Rahman F, Gentle D, Vreeswijk MP, Devilee P, Knowles MA, Ceylaner S, Trembath RC, Dalence C, Kismet E, K\u00f6seo\u011flu V, Rossbach HC, Gissen P, Tannahill D, Maher ER. Mutations in SLC29A3, encoding an equilibrative nucleoside transporter ENT3, cause a familial histiocytosis syndrome (Faisalabad histiocytosis) and familial Rosai-Dorfman disease. PLoS Genet. 2010;6(2):e1000833. https:\/\/doi.org\/10.1371\/journal.pgen.1000833.","DOI":"10.1371\/journal.pgen.1000833"},{"issue":"February","key":"586_CR22","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1016\/j.molimm.2020.02.014","volume":"121","author":"D \u00c7a\u011fda\u015f","year":"2020","unstructured":"\u00c7a\u011fda\u015f D, S\u00fcr\u00fcc\u00fc N, Tan \u00c7, Kayao\u011flu B, \u00d6zg\u00fcl RK, Akkaya-Ulum YZ, et al. Autoinflammation in addition to combined immunodeficiency: SLC29A3 gene defect. Mol Immunol. 2020;121(February):28\u201337. https:\/\/doi.org\/10.1016\/j.molimm.2020.02.014.","journal-title":"Mol Immunol"},{"issue":"5","key":"586_CR23","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1007\/s10875-016-0301-6","volume":"36","author":"A Mistry","year":"2016","unstructured":"Mistry A, Parry D, Matthews B, Laws P, Goodfield M, Savic S. A case of SLC29A3 Spectrum disorder\u2014unresponsive to multiple immunomodulatory therapies. J Clin Immunol. 2016;36(5):429\u201333. https:\/\/doi.org\/10.1007\/s10875-016-0301-6.","journal-title":"J Clin Immunol"},{"key":"586_CR24","unstructured":"Sciascia S, Apr\u00e0 F, Baffa A, Baldovino S, Boaro D, Boero R, et al. Pilot prospective open, single-arm multicentre study on off-label use of tocilizumab in patients with severe COVID-19. Clin Exp Rheumatol. 2020:1\u20134 Available from: http:\/\/www.ncbi.nlm.nih.gov\/pubmed\/32359035."},{"key":"586_CR25","first-page":"200642","volume":"2020","author":"T Ai","year":"2019","unstructured":"Ai T, Yang Z, Hou H, Zhan C, Chen C, Lv W, et al. Correlation of chest CT and RT-PCR testing in coronavirus disease 2019 (COVID-19) in China: a report of 1014 cases. Radiology. 2019;2020:200642.","journal-title":"Radiology."}],"container-title":["Pediatric Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12969-021-00586-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12969-021-00586-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,6,30]],"date-time":"2021-06-30T09:06:34Z","timestamp":1625043994000},"score":1,"resource":{"primary":{"URL":"https:\/\/ped-rheum.biomedcentral.com\/articles\/10.1186\/s12969-021-00586-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,6,30]]},"references-count":25,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["586"],"URL":"https:\/\/doi.org\/10.1186\/s12969-021-00586-2","relation":{},"ISSN":["1546-0096"],"issn-type":[{"value":"1546-0096","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,6,30]]},"assertion":[{"value":"14 December 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 April 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 June 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval was obtained according to local protocols.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Consent for publication was obtain from the parents of the child.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"104"}}